Trial Profile
A Study to Evaluate Safety and Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 24 Sep 2014 New source identified and integrated (European Clinical Trials Database - 2009-011022-33).
- 24 Sep 2014 New trial record